Who are AZD9833 with everolimus's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Afinitor, Torisel, SIROLIMUS, Rapamune, sirolimus (drug), mmf (drug), sirolimus, tacrolimus, mycophenolate mofetil.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/azd9833-with-everolimus.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

AZD9833 with everolimus — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AZD9833 with everolimus (AZD9833 with everolimus) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SERD. Area: Oncology.

phase 1 SERD mTOR Oncology Small molecule Live · refreshed every 30 min

Target snapshot

AZD9833 with everolimus (AZD9833 with everolimus) — AstraZeneca. mTOR inhibitor

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
AZD9833 with everolimus TARGET	AZD9833 with everolimus	AstraZeneca	phase 1	SERD	mTOR
Afinitor	everolimus	Novartis	marketed	Kinase Inhibitor [EPC]	Serine/threonine-protein kinase mTOR	2009-01-01
Torisel	temsirolimus	Pfizer	marketed	Kinase Inhibitor	Serine/threonine-protein kinase mTOR	2007-01-01
SIROLIMUS	SIROLIMUS		marketed	mTOR Inhibitor Immunosuppressant [EPC]	mTOR	1999-01-01
Rapamune	sirolimus	Pfizer	marketed	mTOR Inhibitor Immunosuppressant [EPC]	Serine/threonine-protein kinase mTOR	1999-01-01
sirolimus (drug), mmf (drug)	sirolimus (drug), mmf (drug)	University Hospital Muenster	marketed	Immunosuppressive agents (mTOR inhibitor + IMPDH inhibitor combination)	mTOR (sirolimus); IMPDH type II (MMF)
sirolimus, tacrolimus, mycophenolate mofetil	sirolimus, tacrolimus, mycophenolate mofetil	National Taiwan University Hospital	marketed	Immunosuppressive agent combination	mTOR, calcineurin, IMPDH

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-07-01 — Afinitor · 9006224 · Method of Use · US
2029-02-14 — Rapamune · 8911786 · Formulation · US
2030-04-15 — Rapamune · 10206887 · Formulation · US
2036-03-05 — Rapamune · 12061183 · Formulation · US
2036-03-05 — Rapamune · 10705070 · Formulation · US
2036-06-29 — Rapamune · 10973806 · Method of Use · US
2036-06-29 — Rapamune · 12133844 · Method of Use · US
2040-10-28 — Rapamune · 11497737 · Formulation · US

Sponsor landscape (SERD class)

AstraZeneca · 2 drugs in this class
Xuanzhu Biopharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AZD9833 with everolimus — Competitive Intelligence Brief. https://druglandscape.com/ci/azd9833-with-everolimus. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab